公司問答丨奧比中光:將參加世界機器人大會 期間展示公司3D視覺感知技術系列產品
格隆匯8月10日丨有投資者在互動平台向奧比中光(688322.SH)提問:2023世界機器人大會下週要召開了,公司會不會參加本次的機器人大會,參加的話會展示那些產品,尤其是有沒有新產品?奧比中光回覆:2023世界機器人大會將於2023年8月16日至22日在北京召開,公司將參加本次世界機器人大會並設置專門展位,期間將展示公司3D視覺感知技術系列產品(包括公司近期發佈的3D開發套件Persee N1、Orbbec Gemini 2 L及Orbbec Astra 2 等),並提供3D視覺解決方案現場體驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.